Abstract:Abstract Background Soluble beta-amyloid (Aβ) can be cleared from the brain through various mechanisms including enzymatic degradation, glial cell phagocytosis, transport across the blood-brain barrier, and glymphatic clearance. However, the relative contribution of each clearance system and their compensatory effects in delaying the pathological process of Alzheimer’s disease (AD) are currently unknown. Methods Fluorescent trace, immunofluorescence, and Western blot analyses were performed to compare glymphatic clearance ability and Aβ accumulation among 3-month-old APP695/PS1-dE9 transgenic (APP/PS1) mice, wild-type mice, aquaporin 4 knock out (AQP4 −/− ) mice, and AQP4 −/− /APP/PS1 mice. The consequence of selectively eliminating microglial cells, or downregulating apolipoprotein E (apoE) expression, on Aβ burden, was also investigated in the frontal cortex of AQP4 −/− /APP/PS1 mice and APP/PS1 mice. Results AQP4 deletion in APP/PS1 mice significantly exaggerated glymphatic clearance dysfunction, and intraneuronal accumulation of Aβ and apoE, although it did not lead to Aβ plaque deposition. Notably, microglia, but not astrocytes, increased activation and phagocytosis of Aβ in the cerebral cortex of AQP4 −/− /APP/PS1 mice, compared with APP/PS1 mice. Selectively eliminating microglia in the frontal cortex via local injection of clodronate liposomes resulted in deposition of Aβ plaques in AQP4 −/− /APP/PS1 mice, but not APP/PS1 mice. Moreover, knockdown of apoE reduced intraneuronal Aβ levels in both APP/PS1 mice and AQP4 −/− /APP/PS1 mice, indicating an inhibitory effect of apoE on Aβ clearance. Conclusion The above results suggest that the glymphatic system mediated Aβ and apoE clearance and microglia mediated Aβ degradation synergistically prevent Aβ plague formation in the early stages of the AD mouse model. Protecting one or both of them might be beneficial to delaying the onset of AD.

Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model

Astrocyte-Microglia Cross Talk through Complement Activation Modulates Amyloid Pathology in Mouse Models of Alzheimer's Disease.

Microglial NF-κB drives tau spreading and toxicity in a mouse model of tauopathy

Microglial Drivers of Alzheimer's Disease Pathology: An Evolution of Diverse Participating States

Microglia in the Neuroinflammatory Pathogenesis of Alzheimer's Disease and Related Therapeutic Targets

ApoE isoform– and microbiota-dependent progression of neurodegeneration in a mouse model of tauopathy

The Neuro-Inflammatory Microenvironment: an Important Regulator of Stem Cell Survival in Alzheimer’s Disease

Microglia and microglial-based receptors in the pathogenesis and treatment of Alzheimer's disease

APOE4 impairs the microglial response in Alzheimer's disease by inducing TGFβ-mediated checkpoints

Tau pathology epigenetically remodels the neuron-glial cross-talk in Alzheimer's disease

Microglial apolipoprotein E particles contribute to neuronal senescence and synaptotoxicity

Microglia prevent beta-amyloid plaque formation in the early stage of an Alzheimer’s disease mouse model with suppression of glymphatic clearance

Alzheimer’s disease-linked risk alleles elevate microglial cGAS-associated senescence and neurodegeneration in a tauopathy model

Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia

Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer's disease

APOE4 Impairs Microglia ‐ Astrocyte Crosstalk in Alzheimer Disease

Microglia in Alzheimer’s disease

Microglia contributes to plaque growth by cell death due to uptake of amyloid β in the brain of Alzheimer's disease mouse model

Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer’s disease

Emerging microglial biology highlights potential therapeutic targets for Alzheimer's disease

Microglial purinergic signaling in Alzheimer's disease